Rheum Round-up: Interviews with Authors of ‘Untold Stories’ of Female Surgeons, and more
Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read two interviews with the authors of...
Rheum Round-up: Latest Baricitinib Research, Autoimmune Diseases and COVID-19, and more
Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about the latest studies on Eli...
Upadacitinib versus Abatacept: How Do These Rheumatoid Arthritis Drugs Compare?
A study that put rheumatoid arthritis drugs upadacitinib and abatacept head-to-head yielded mixed results: upadacitinib was associated with better disease outcomes, but at the...
The Latest Research on Baricitinib, Eli Lilly’s Arthritis Drug Used to Treat COVID-19
Eli Lilly’s rheumatoid arthritis (RA) drug baricitinib, marketed as Olumiant, has been the subject of several clinical trials in the fight to treat COVID-19....
Rheum Round-up: Sexual Harassment in Orthopedics, RA Drug Analysis, and more
Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about the rate of sexual harassment...
Did COVID-19 Affect Outcomes for Inflammatory Rheumatic Disease Patients?
The COVID-19 pandemic does not appear to have significantly affected the disease course of patients with inflammatory rheumatic diseases including axial spondyloarthritis (axSpA), rheumatoid...
Infliximab and Golimumab: Are These Anti-TNF Agents Suitable for Long-Term RA Treatment?
A long-term registry study evaluating the effectiveness of infliximab, golimumab, and intravenous (IV) golimumab in patients with rheumatoid arthritis (RA) found that the treatments...
